Theodore Geh-lu Liou, MD | |
50 N Medical Dr, Salt Lake City, UT 84132-0001 | |
(801) 581-7806 | |
Not Available |
Full Name | Theodore Geh-lu Liou |
---|---|
Gender | Male |
Speciality | Pulmonary Disease |
Experience | 38 Years |
Location | 50 N Medical Dr, Salt Lake City, Utah |
Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1588754196 | NPI | - | NPPES |
110113199 | Other | UT | RAILROAD MEDICARE |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207RP1001X | Internal Medicine - Pulmonary Disease | 182794-1205 (Utah) | Secondary |
207RC0200X | Internal Medicine - Critical Care Medicine | 182794-1205 (Utah) | Primary |
Facility Name | Location | Facility Type |
---|---|---|
University Of Utah Hospitals And Clinics | Salt lake city, UT | Hospital |
Group Practice Name | Group PECOS PAC ID | No. of Members |
---|---|---|
University Of Utah Adult Services | 0941525273 | 1459 |
News Archive
AlerSense Incorporated has created the world's first smart airborne allergy and asthma early warning system alerting consumers as particles and toxins build. AlerSense is an in-home unit when, combined with the mobile app, delivers accurate environmental readings, giving asthma and allergy sufferers precious time to remove themselves from, or alter the environment to possibly mitigate or avoid an allergy or asthma attack.
Infinity Pharmaceuticals, Inc. today announced interim data from its Phase 2, double-blind, randomized, placebo-controlled study of saridegib (IPI-926) in patients with metastatic or locally advanced, inoperable chondrosarcoma. The primary endpoint of the Phase 2 study was progression-free survival.
IRD scientist and their research partners recently identified the key role of nicotinamidase, an enzyme in the parasite Leishmania, essential for its survival but which does not exist in humans. The pathogen is incapable of developing in mammals In the absence of this enzyme. Specific targeting of this enzyme could lead to more effective ways of controlling this neglected tropical disease.
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, today announced that it has received Notice of Allowance from the U.S. Patent and Trademark Office for its patent application "Abuse-Deterrent Drug Formulations", US Patent Application Number 11/149,867. The Notice of Allowance is the USPTO's official communication that the Company's application has successfully completed examination and that a patent will be issued.
The National Institute for Health and Care Excellence has recommended a new treatment to help patients suffering from blood clots in the legs and lungs.
› Verified 1 days ago
Entity Name | University Of Utah Acuity Care Services |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1407250541 PECOS PAC ID: 4789908534 Enrollment ID: O20150127000392 |
News Archive
AlerSense Incorporated has created the world's first smart airborne allergy and asthma early warning system alerting consumers as particles and toxins build. AlerSense is an in-home unit when, combined with the mobile app, delivers accurate environmental readings, giving asthma and allergy sufferers precious time to remove themselves from, or alter the environment to possibly mitigate or avoid an allergy or asthma attack.
Infinity Pharmaceuticals, Inc. today announced interim data from its Phase 2, double-blind, randomized, placebo-controlled study of saridegib (IPI-926) in patients with metastatic or locally advanced, inoperable chondrosarcoma. The primary endpoint of the Phase 2 study was progression-free survival.
IRD scientist and their research partners recently identified the key role of nicotinamidase, an enzyme in the parasite Leishmania, essential for its survival but which does not exist in humans. The pathogen is incapable of developing in mammals In the absence of this enzyme. Specific targeting of this enzyme could lead to more effective ways of controlling this neglected tropical disease.
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, today announced that it has received Notice of Allowance from the U.S. Patent and Trademark Office for its patent application "Abuse-Deterrent Drug Formulations", US Patent Application Number 11/149,867. The Notice of Allowance is the USPTO's official communication that the Company's application has successfully completed examination and that a patent will be issued.
The National Institute for Health and Care Excellence has recommended a new treatment to help patients suffering from blood clots in the legs and lungs.
› Verified 1 days ago
Entity Name | University Of Utah Adult Services |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1114321981 PECOS PAC ID: 0941525273 Enrollment ID: O20150209001683 |
News Archive
AlerSense Incorporated has created the world's first smart airborne allergy and asthma early warning system alerting consumers as particles and toxins build. AlerSense is an in-home unit when, combined with the mobile app, delivers accurate environmental readings, giving asthma and allergy sufferers precious time to remove themselves from, or alter the environment to possibly mitigate or avoid an allergy or asthma attack.
Infinity Pharmaceuticals, Inc. today announced interim data from its Phase 2, double-blind, randomized, placebo-controlled study of saridegib (IPI-926) in patients with metastatic or locally advanced, inoperable chondrosarcoma. The primary endpoint of the Phase 2 study was progression-free survival.
IRD scientist and their research partners recently identified the key role of nicotinamidase, an enzyme in the parasite Leishmania, essential for its survival but which does not exist in humans. The pathogen is incapable of developing in mammals In the absence of this enzyme. Specific targeting of this enzyme could lead to more effective ways of controlling this neglected tropical disease.
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, today announced that it has received Notice of Allowance from the U.S. Patent and Trademark Office for its patent application "Abuse-Deterrent Drug Formulations", US Patent Application Number 11/149,867. The Notice of Allowance is the USPTO's official communication that the Company's application has successfully completed examination and that a patent will be issued.
The National Institute for Health and Care Excellence has recommended a new treatment to help patients suffering from blood clots in the legs and lungs.
› Verified 1 days ago
Mailing Address | Practice Location Address |
---|---|
Theodore Geh-lu Liou, MD Po Box 413033, Salt Lake City, UT 84141-3033 Ph: (801) 213-3900 | Theodore Geh-lu Liou, MD 50 N Medical Dr, Salt Lake City, UT 84132-0001 Ph: (801) 581-7806 |
News Archive
AlerSense Incorporated has created the world's first smart airborne allergy and asthma early warning system alerting consumers as particles and toxins build. AlerSense is an in-home unit when, combined with the mobile app, delivers accurate environmental readings, giving asthma and allergy sufferers precious time to remove themselves from, or alter the environment to possibly mitigate or avoid an allergy or asthma attack.
Infinity Pharmaceuticals, Inc. today announced interim data from its Phase 2, double-blind, randomized, placebo-controlled study of saridegib (IPI-926) in patients with metastatic or locally advanced, inoperable chondrosarcoma. The primary endpoint of the Phase 2 study was progression-free survival.
IRD scientist and their research partners recently identified the key role of nicotinamidase, an enzyme in the parasite Leishmania, essential for its survival but which does not exist in humans. The pathogen is incapable of developing in mammals In the absence of this enzyme. Specific targeting of this enzyme could lead to more effective ways of controlling this neglected tropical disease.
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, today announced that it has received Notice of Allowance from the U.S. Patent and Trademark Office for its patent application "Abuse-Deterrent Drug Formulations", US Patent Application Number 11/149,867. The Notice of Allowance is the USPTO's official communication that the Company's application has successfully completed examination and that a patent will be issued.
The National Institute for Health and Care Excellence has recommended a new treatment to help patients suffering from blood clots in the legs and lungs.
› Verified 1 days ago
Dr. Mehmet Akkaya, M.D Critical Care Medicine Medicare: Medicare Enrolled Practice Location: University Of Utah Hospital Cardiology, 3o N,1900 E, Rm:4a100, Salt Lake City, UT 84132 Phone: 801-505-1689 | |
Dr. Willard Dere, M.D. Critical Care Medicine Medicare: Not Enrolled in Medicare Practice Location: 500 Foothill Blvd, Salt Lake City, UT 84148 Phone: 801-582-1565 | |
Megan Meier, MD Critical Care Medicine Medicare: Medicare Enrolled Practice Location: 50 N Medical Dr, Salt Lake City, UT 84132 Phone: 801-581-2121 | |
Joel Money, MD Critical Care Medicine Medicare: Medicare Enrolled Practice Location: 50 N Medical Dr, Salt Lake City, UT 84132 Phone: 801-581-2121 | |
Mchale O. Anderson, MD Critical Care Medicine Medicare: Medicare Enrolled Practice Location: 30 N 1900 E Rm 4a100, Salt Lake City, UT 84132 Phone: 801-587-2451 | |
Siddharth K. Iyengar, MD Critical Care Medicine Medicare: Medicare Enrolled Practice Location: 30 N 1900 E Rm 4c116, Salt Lake City, UT 84132 Phone: 801-581-7606 | |
Taryn A. Young, MD Critical Care Medicine Medicare: Medicare Enrolled Practice Location: 5121 S Cottonwood St, Salt Lake City, UT 84107 Phone: 801-507-4384 Fax: 801-507-4398 |